Figure 6
Figure 6. Improved clotting in treatment-naive, severe hemophilia A dogs after oral AV513 administration. Citrated whole blood from severe hemophilia A dogs prepared before and at the end of each dosing period was evaluated for clot formation in the TEG assay. (A). TEG R time averaged from 3 dogs after each dose (with SD) is represented as a bar graph. (*P = .001 compared with baseline). (B) Citrated whole blood from severe hemophilia A dogs prepared before and after the last dose of 20mg/kg were evaluated for clotting in the TEG assay. TEG R times were averaged from 3 dogs and are represented as a bar graph (with SD). (*P = .002 compared with baseline). The 2-hour preanalyses were performed with blood drawn 2 hours before the last dose (ie, 15 hours after the previous dose), while the 2-hour postanalyses were performed with blood drawn 2 hours after the last dose.

Improved clotting in treatment-naive, severe hemophilia A dogs after oral AV513 administration. Citrated whole blood from severe hemophilia A dogs prepared before and at the end of each dosing period was evaluated for clot formation in the TEG assay. (A). TEG R time averaged from 3 dogs after each dose (with SD) is represented as a bar graph. (*P = .001 compared with baseline). (B) Citrated whole blood from severe hemophilia A dogs prepared before and after the last dose of 20mg/kg were evaluated for clotting in the TEG assay. TEG R times were averaged from 3 dogs and are represented as a bar graph (with SD). (*P = .002 compared with baseline). The 2-hour preanalyses were performed with blood drawn 2 hours before the last dose (ie, 15 hours after the previous dose), while the 2-hour postanalyses were performed with blood drawn 2 hours after the last dose.

Close Modal

or Create an Account

Close Modal
Close Modal